CCR5 antagonists inhibit HIV entry by binding to coreceptor and inducing changes in the extracellular loops (ECLs) of CCR5. In this study, we analyzed viruses from eleven treatmentexperienced patients who experienced virologic failure on treatment regimens containing the CCR5 antagonist maraviroc (MVC). Viruses from one patient developed high-level resistance to MVC during the course of treatment. Although resistance to one CCR5 antagonist is often associated with broad cross-resistance to other agents, these viruses remained sensitive to most other CCR5 antagonists including vicriviroc and aplaviroc. MVC resistance was dependent upon mutations within the V3 loop of the viral envelope (Env) protein and was modulated by additional mutations in the V4 loop. Deep sequencing of pretreatment plasma viral RNA indicated that resistance appears to have occurred by evolution of drug-bound CCR5 use, despite the presence of viral sequences predictive of CXCR4 use. Envs obtained from this patient before and during MVC treatment were able to infect cells expressing very low CCR5 levels, indicating highly efficient use of coreceptor. In contrast to previous reports in which CCR5 antagonistresistant viruses interact with predominantly the N-terminus of CCR5, these MVC-resistant Envs were also dependent upon the drug-modified ECLs of CCR5 for entry. Our results suggest a model of CCR5 cross-resistance whereby viruses that predominantly utilize the N-terminus are broadly cross-resistant to multiple CCR5 antagonists whereas viruses that require both the Nterminus and antagonist-specific ECL changes demonstrate a narrow cross-resistance profile.
Introduction
Small-molecule CCR5 antagonists are a relatively new class of drugs that block HIV entry into target cells with the first member of this class, maraviroc (MVC), having been approved for the treatment of HIV-infected patients. These drugs bind to a hydrophobic pocket formed by the transmembrane helices of CCR5, inducing conformational changes in the extracellular loops (ECLs) of the receptor (18, 31, 39, 40, 58, 62, 64) . These conformational changes can vary with different drugs, as evidenced by differential chemokine binding and HIV resistance profiles, and block the ability of HIV to use drug-bound CCR5 as a coreceptor for entry (59, 64) .
As with other antiretroviral agents, HIV can develop resistance to CCR5 antagonists. One pathway by which HIV can become resistant to CCR5 antagonists is via mutations in the viral envelope (Env) protein that enable it to recognize the drug-bound conformation of the coreceptor. Most of our information on this pathway has come from in vitro passaging of HIV-1 in the presence of increasing concentrations of inhibitor (2, 4, 5, 33, 41, 44, 61, 66) . In most instances, the viral determinants of resistance are localized to the V3 loop of gp120 (5, 33, 41, 44, 46, 63, 66) . This is as expected: the base of the V3 loop interacts with O-sulfated tyrosines in the N-terminus of CCR5, while the tip of the V3 loop is thought to contact the ECLs of the receptor (14, 15, 17, 19, 26, 29, 37) . Viral resistance to one CCR5 antagonist commonly results in cross-resistance to other drugs in this class, although this is not universally the case (33, 41, 60, 63, 66) . Mechanistically, a number of CCR5 antagonist-resistant viruses have been shown to have increased dependence on the N-terminal domain of CCR5 (5, 34, 44, 45, 48) , which is largely unaffected by drug binding and may allow viruses to tolerate drug-induced changes in ECL conformation. In contrast to several well-characterized viruses that have evolved resistance to CCR5 antagonist in vitro, few examples of patient-derived CCR5 antagonist-resistant viruses have been reported. One mechanism of resistance that has been described in patients is the outgrowth of CXCR4-tropic HIV isolates that were present at low frequency prior to initiation of therapy (22, 23, 35, 36, 42, 65) . Due to this finding, patients undergo tropism testing prior to treatment with CCR5 antagonists, with only those harboring exclusively R5-tropic viruses considered candidates for therapy. Patient-derived viruses capable of using drug-bound CCR5 have been reported in studies using vicriviroc and aplaviroc (45, 60, 63) . The aplaviroc-resistant viruses were determined to utilize the drug-bound form of the receptor by interacting primarily with the N-terminus of CCR5, similar to the viruses derived by serial in vitro passaging (48) .
In the present study, we report the isolation of MVC-resistant Envs from a treatmentexperienced patient who had viral load rebound while on a regimen containing MVC. Viral Envs isolated from this patient at the time MVC therapy was initiated were fully sensitive to drug. However, resistance evolved over the course of 224 days, culminating in Envs that were completely resistant to inhibition but continued to use CCR5 for entry. The emergence of resistance was dependent upon changes within the V3 loop of the virus, while changes in the V4 loop modulated the magnitude of resistance. The MVC-resistant Envs studied here exhibited several unusual properties. First, while they were cross-resistant to TAK779, they remained sensitive to all other CCR5 antagonists tested, including vicriviroc and aplaviroc. Second, the Envs were particularly adept at utilizing low levels of CCR5 to mediate infection of cells. Third, and in contrast to several recent reports of CCR5 antagonist-resistant viruses, these Envs were dependent upon residues within both the N-terminus and ECLs of CCR5 for efficient entry in the presence of drug. When considered in the context of other reports, our data suggest a model in 
Methods
Study Population. All subjects for this study were identified from the ongoing clinic-based cohort of HIV-infected persons followed at two academic clinics in San Francisco (the SCOPE cohort). This cohort was enriched for patients with highly resistant HIV who were initiating "salvage" regimens containing an integrase inhibitor and/or a CCR5 antagonist when these drugs became more widely available (24) . From this cohort, we identified all individuals who initiated a regimen containing maraviroc who exhibited evidence of incomplete viral suppression (defined as failure to achieve an undetectable plasma HIV RNA level or persistently detectable plasma HIV RNA levels after having achieved undetectable levels). Subjects who received therapy in controlled clinical trials were eligible as long as their treatment assignment was subsequently determined. Plasma samples were collected and stored approximately every four months. All subjects provided written informed consent to have samples collected for these types of studies.
This study was approved by the UCSF Institutional Review Board.
Cloning of patient envs. Cloning of envs from patients plasma was performed using multiple separate PCR reactions using a high-fidelity polymerase with 3'-to-5' proofreading exonuclease activity as previously described (30) . Vectors were grown in Stbl-3 E. coli at 30°C to minimize bacterially-induced mutagenesis and recombination of env. Mutant and chimeric envs were created by site-directed mutagenesis and overlap PCR, respectively, and were confirmed by sequencing.
Virus infection assays.
Patient envs digested with KpnI and XbaI were subcloned into a pCI expression construct containing hepatitis B virus PRE to enable high-level, rev-independent Env expression. Pseudotyped viruses were produced from 293T/17 cells (30 µg pCI-PRE-env vector on July 1, 2017 by guest http://jvi.asm.org/ Downloaded from and 10 µg of pNL-luc-Env-core(9, 12)), and 5-25 ng p24 equivalent were used to infect cell lines, amounts empirically determined to be in the linear range of the infection assay. Cells were spinoculated with virus at 450g for 2 hours at 25°C. Three days post-infection, cells were lysed and luciferase activity analyzed on a luminometer. For inhibition assays, cells were preincubated with CCR5 antagonists or enfuvirtide for 30 minutes at 37°C prior to spinoculation with virus. 454 pyrophosphate sequencing. Viral RNA was extracted from 140 µl of human plasma from the day 1 time point from patient 6061 using the QIAamp viral RNA kit (Qiagen).
cDNA synthesis was performed on isolated viral RNA using Superscript III reverse transcriptase (Invitrogen) and the subtype B primer TTGCTACTTGTGATTGCTCCATGT.
For V3 loop amplification, a nested PCR approach was used. First, cDNA product was amplified in each of 8 to 16 different PCR reactions as mentioned previously. Multiple PCR reactions were performed simultaneously to ensure sequence diversity. One µl of the first round PCR product was then used for each of 16 corresponding second round PCR reactions.
The second round PCR was performed using subtype B specific primers described by Rozera and colleagues that were modified to contain an 8bp DNA barcode and the 454 adaptor sequences (25, 53) . Consensus subtype B primers were used to reduce amplification bias.
Emulsion PCR was then performed, followed by pyrosequencing using a Roche/454 and IgG b12 were obtained from the IAVI Neutralizing Antibody Consortium repository. Cells were assayed for luciferase expression after 3 days.
Affinofile assay. Infection of the HEK293-based CD4/CCR5 dual-inducible cell line (293-Affinofile) with luciferase-based pseudoviruses was performed as previously described (28) .
Briefly, 96 well plates were seeded with 1.0 x 10 4 inducible cells two days prior to CD4 and CCR5 induction. Cells were induced using two-fold serial dilutions from 5 ng to 0.156 ng/ml of minocycline (resulting in 6 induction conditions for CD4) and from 2 to 0.0156 µM of ponasterone A (resulting in 8 induction conditions for CCR5). Cells were incubated for 18 hours at 37°C, after which induction media was removed, half the plates were preincubated with 10 µM maraviroc for 30 min and then were infected with pseudoviruses normalized for p24 content.
Infection was quantified after 3 days as described above. cDNA, and performing amplification of full-length env sequences using a nested PCR strategy.
Mutant
Viral env V3 loop sequences were examined for evidence of CXCR4 use, which is a wellcharacterized mechanism of escape from CCR5 antagonists (22, 23, 35, 36, 42, 65) . Six of 11 patients were found to have basic residues at positions 11, 24, and/or 25 of the V3 loop, which are highly predictive of CXCR4 use (8, 16, 20, 21, 27, 51) . The remaining 5 patients had very few or no CXCR4-using viruses defined by sequencing. The envs from these patients were subcloned into expression vectors and pseudoviral particles were produced. The viruses pseudotyped with Envs from these 5 patients were strictly R5-tropic as determined by their ability to infect NP2 cells expressing CD4 and CCR5, but not CD4 and CXCR4 (data not shown).
To determine the MVC susceptibility of the cloned Envs, pseudotype infection assays 13.6%). In contrast, chimeras containing the V4 loops alone exhibited similar resistance profiles as the parental strains. These data suggest that the V4 loops from this patient do not confer resistance to MVC, but modulate the magnitude of resistance.
To map the MVC resistance determinants with higher precision, we individually changed the three V3 loop mutations back to the baseline sequences in the resistant clone using sitedirected mutagenesis. Pseudoviral particles bearing the three revertants, H308P, H320T, and V322aI all infected NP2/CD4/CCR5 cells efficiently. In the presence of 10 µM MVC, pseudoviruses bearing the resistant Env with the H308P mutation were strongly inhibited by MVC (MPI = 88.3%), whereas the H320T and V322aI revertants retained most of their resistance to MVC (MPI=17.3% and 9.4%, respectively) ( Figure 2B ). Together, these data indicate that the V3 loop played a major role in conferring resistance to MVC with the P/T308H mutation playing the most important role, but that additional mutations outside of the V3 loop contributed to the extent of resistance.
Resistance determinants within the V3 loop can transfer resistance to heterologous viruses. Previous studies of CCR5 antagonist-resistant viruses have identified resistance determinants that were dependent upon the parental Env context and did not transfer resistance when introduced into other viruses (2, 46, 48) . To test whether the V3 loop alone from the MVC- three of the mutations found in MVC-resistant clones (H308, H320, and V322a). In addition, of the three residues sufficient to confer partial MVC resistance, we detected only seven sequences with the major MVC-resistance conferring mutation, H308 (0.016%), no sequences with H320, and 5,966 sequences with V322a (13.8%) ( Table 1) . Notably, the seven sequences with H308 had the MVC sensitive residues at all other V3 loop positions.
While we cannot exclude the possibility that clones containing all resistance mutations existed either below a frequency of 1 in 40,000 or in sites other than plasma, it appears more likely that the mutations associated with MVC resistance emerged during the course of treatment. Consistent with this hypothesis, two of the Envs we analyzed at the intermediate time point (Figure 1A ) contained the H308 and V322a mutations, but not the H320 mutation.
In addition, sequences consistent with CXCR4 usage existed at a frequency of approximately 0.5% in the pretreatment viral reservoir, yet viral resistance to MVC emerged due to evolution of drug-bound CCR5 usage rather than outgrowth of CXCR4-using viruses. These data indicate that the Envs from patient 6061 are unusually adept at infecting cells expressing very low levels of CCR5, provided that CD4 expression levels are adequate.
MVC resistance is associated with increased sensitivity to soluble CD4 and b12.
To provide insight into the exposure of the CD4 and coreceptor binding sites that would account for the unusual ability of these MVC-resistant viruses to infect cells expressing low CCR5 levels, as well as to determine whether MVC resistance was associated with increased sensitivity to neutralization, we performed infection assays in which pseudotypes bearing a MVC-resistant or a MVC-sensitive Env were preincubated with sCD4, monoclonal antibodies (MAbs), or HIV-Ig and used to infect NP2/CD4/CCR5 cells ( Figure 4A-F) . In these assays, the pseudotypes bearing the MVC-resistant Env were significantly more sensitive to inhibition by sCD4 and b12 (p<0.02 for both), equally sensitive to 17b, and On wild-type CCR5, the MVC-resistant clone exhibited an MPI of -5.9 ± 15.7% (Table   2) . Consistent with previous studies, residues within the N-terminus of CCR5 were critical for the ability of the MVC-resistant virus to utilize drug-bound receptor. The tyrosine mutants viruses that utilize CXCR4 as a coreceptor for entry (23, 35, 65) . In most cases, this appears to be due to the selective outgrowth of minor CXCR4-utilizing variants that were pre-existing in the patients' viral reservoirs prior to treatment and which gain a selective advantage during CCR5
antagonist therapy. In other cases, viruses replicating in the presence of CCR5 antagonists either in vitro or in vivo have evolved resistance by acquiring the ability to utilize the drug-bound conformation of CCR5 for entry while still retaining the ability to efficiently utilize the drug-free conformation of CCR5 (2, 4, 33, 41, 44, 60, 61, 63, 66) . In most instances described to date, such viruses exhibit cross-resistance to multiple CCR5 antagonists (33, 41, 60) . Less commonly, a more narrow drug-resistance profile is observed (66) . For example, the MVC-resistant viruses studied here remain sensitive to most other CCR5 antagonists. Together, these observations indicate that resistance to CCR5 antagonists entails a variable degree of conformational plasticity with regards to CCR5 recognition. In all cases drug-resistant viruses are able to efficiently utilize the drug-free conformation of CCR5, and in addition at least one and more often multiple drugbound conformations are recognized with variable efficiency. In this study, we sought to explore the mechanisms that account for these different phenotypes.
There is ample precedent for variable Env-coreceptor recognition. Mutations introduced into CCR5 can have differential effects on infection by different HIV-1 strains (3, 6, 17, 29, 32, 38, 49, 54) . In many ways, R5X4 viruses represent an extreme example of this property, as they are able to efficiently utilize both CCR5 and CXCR4 despite significant differences in the antagonists, and sometimes viruses that exhibit a narrow drug-resistance profile. There are clearly selective pressures against the emergence of CXCR4-using viruses, since these typically fail to arise until years after infection and often fail to evolve to detectable levels (1, 7, 10, 11, 13, 47, 57) . In the patient studied here, deep sequencing revealed the presence of V3 sequences consistent with use CXCR4 for entry at a frequency of approximately 0.5% in the pretreatment sample. These findings indicate that the presence of X4-tropic HIV variants at baseline does not necessarily predict that patients will fail CCR5 antagonist therapy by outgrowth of these X4 viruses, and raises the possibility that these agents may have some efficacy in certain patients harboring dual/mixed viral populations. In contrast, no sequences containing all three of the mutations associated with resistance in this patient were present at baseline, suggesting that de novo viral evolution to use MVC-bound CCR5 was favored over outgrowth of CXCR4-using viruses. Using the newly developed affinofile assay by Lee and colleagues (28) , which allows detailed characterization of viral requirements for CD4 and CCR5 levels, we found that the MVC-resistant viruses described here as well as aplaviroc-resistant Envs derived from a second patient were unusual in their ability to efficiently utilize low levels of CCR5 for virus infection (48) . Although speculative, it is possible that the ability to utilize very low levels of CCR5 for entry reflects highly efficient use of CCR5, and that viruses that utilize CCR5 very efficiently may be able to tolerate mutations within the V3 loop without abolishing infectivity. Some of these mutations, in turn, may enable the virus to utilize drugbound CCR5 more efficiently and give rise to drug-resistant variants. Further studies with resistant viruses and their requirements for CCR5 levels will be necessary to test this hypothesis. 
